Reuters logo
BRIEF-Invivo Therapeutics qtrly adjusted net loss per diluted share 0.21
March 10, 2017 / 9:54 PM / 8 months ago

BRIEF-Invivo Therapeutics qtrly adjusted net loss per diluted share 0.21

March 10 (Reuters) - Invivo Therapeutics Holdings Corp :

* Invivo Therapeutics reports 2016 year-end financial results and business update

* Invivo Therapeutics Holdings Corp qtrly GAAP net loss per diluted share $0.17

* Qtrly adjusted net loss per diluted share 0.21

* Invivo Therapeutics holdings- “ended year with about $33 million in cash, cash equivalents, and marketable securities that we project will fund us into q2 of 2018”

* Expect to submit HDE application for marketing approval of neuro-spinal scaffold by q2 2018

* Plan to initiate first study in cervical SCI in Canada in coming months Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below